Safeguarding children's rights in psychopharmacological research

Ethical and legal issues

Michael Kölch, Andrea G. Ludolph, Paul L. Plener, Heiner Fangerau, Benedetto Vitiello, Joerg M. Fegert

Research output: Contribution to journalArticle

Abstract

Objective: Research on psychopharmacological treatment in children and adolescents is the subject of ongoing ethical discussion, as minors with mental disorders constitute a vulnerable patient group. Considering the important legislative changes in pediatric research over the past decade in both the US and Western Europe, there is a need to review recent developments in this area. Method: Based on a systematic literature review, a hermeneutical analysis focusing the main issues of ethics in child and adolescent psychopharmacology is provided. Legal and regulatory aspects of psychopharmacological research in children are compared between the US and Europe. Relevant issues were informed assent and consent to research participation, minimal risk and burden of research, ethics of pharmacogenetics, research on "me-too" medications, and justice in global research. Additionally, the concern about undue influence of financial interests in research is also addressed. Conclusion: Incentives for the conduct of clinical trials with children comparable to those contained in US legislation are now provided in the EU. Research to develop "me-too" preparations may have no significant benefit for children, but can cause research burden and detract from clinically more important projects by utilizing limited investigator time and patient resources. Thus far, pharmacogenetic studies may bring more individualized treatment approaches into child psychiatry but they remain at present a promise for the future. Finally, the issues of avoiding undue influence from funders and conflicts of interest remain a prominent concern which can be solved by declaring conflicts and publishing all results of studies extensively.

Original languageEnglish (US)
Pages (from-to)2398-2406
Number of pages9
JournalCurrent Pharmaceutical Design
Volume16
Issue number22
DOIs
StatePublished - 2010
Externally publishedYes

Fingerprint

Ethics
Research
Research Ethics
Minors
Psychopharmacology
Conflict of Interest
Child Psychiatry
Pharmacogenetics
Social Justice
Jurisprudence
Informed Consent
Legislation
Mental Disorders
Motivation
Research Personnel
Clinical Trials
Pediatrics
Therapeutics

Keywords

  • Children and adolescents
  • Ethics
  • Psychopharmacology
  • Research

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Kölch, M., Ludolph, A. G., Plener, P. L., Fangerau, H., Vitiello, B., & Fegert, J. M. (2010). Safeguarding children's rights in psychopharmacological research: Ethical and legal issues. Current Pharmaceutical Design, 16(22), 2398-2406. https://doi.org/10.2174/138161210791959881

Safeguarding children's rights in psychopharmacological research : Ethical and legal issues. / Kölch, Michael; Ludolph, Andrea G.; Plener, Paul L.; Fangerau, Heiner; Vitiello, Benedetto; Fegert, Joerg M.

In: Current Pharmaceutical Design, Vol. 16, No. 22, 2010, p. 2398-2406.

Research output: Contribution to journalArticle

Kölch, M, Ludolph, AG, Plener, PL, Fangerau, H, Vitiello, B & Fegert, JM 2010, 'Safeguarding children's rights in psychopharmacological research: Ethical and legal issues', Current Pharmaceutical Design, vol. 16, no. 22, pp. 2398-2406. https://doi.org/10.2174/138161210791959881
Kölch, Michael ; Ludolph, Andrea G. ; Plener, Paul L. ; Fangerau, Heiner ; Vitiello, Benedetto ; Fegert, Joerg M. / Safeguarding children's rights in psychopharmacological research : Ethical and legal issues. In: Current Pharmaceutical Design. 2010 ; Vol. 16, No. 22. pp. 2398-2406.
@article{6b3fa76d75db4fa18a19d1d181b7901c,
title = "Safeguarding children's rights in psychopharmacological research: Ethical and legal issues",
abstract = "Objective: Research on psychopharmacological treatment in children and adolescents is the subject of ongoing ethical discussion, as minors with mental disorders constitute a vulnerable patient group. Considering the important legislative changes in pediatric research over the past decade in both the US and Western Europe, there is a need to review recent developments in this area. Method: Based on a systematic literature review, a hermeneutical analysis focusing the main issues of ethics in child and adolescent psychopharmacology is provided. Legal and regulatory aspects of psychopharmacological research in children are compared between the US and Europe. Relevant issues were informed assent and consent to research participation, minimal risk and burden of research, ethics of pharmacogenetics, research on {"}me-too{"} medications, and justice in global research. Additionally, the concern about undue influence of financial interests in research is also addressed. Conclusion: Incentives for the conduct of clinical trials with children comparable to those contained in US legislation are now provided in the EU. Research to develop {"}me-too{"} preparations may have no significant benefit for children, but can cause research burden and detract from clinically more important projects by utilizing limited investigator time and patient resources. Thus far, pharmacogenetic studies may bring more individualized treatment approaches into child psychiatry but they remain at present a promise for the future. Finally, the issues of avoiding undue influence from funders and conflicts of interest remain a prominent concern which can be solved by declaring conflicts and publishing all results of studies extensively.",
keywords = "Children and adolescents, Ethics, Psychopharmacology, Research",
author = "Michael K{\"o}lch and Ludolph, {Andrea G.} and Plener, {Paul L.} and Heiner Fangerau and Benedetto Vitiello and Fegert, {Joerg M.}",
year = "2010",
doi = "10.2174/138161210791959881",
language = "English (US)",
volume = "16",
pages = "2398--2406",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "22",

}

TY - JOUR

T1 - Safeguarding children's rights in psychopharmacological research

T2 - Ethical and legal issues

AU - Kölch, Michael

AU - Ludolph, Andrea G.

AU - Plener, Paul L.

AU - Fangerau, Heiner

AU - Vitiello, Benedetto

AU - Fegert, Joerg M.

PY - 2010

Y1 - 2010

N2 - Objective: Research on psychopharmacological treatment in children and adolescents is the subject of ongoing ethical discussion, as minors with mental disorders constitute a vulnerable patient group. Considering the important legislative changes in pediatric research over the past decade in both the US and Western Europe, there is a need to review recent developments in this area. Method: Based on a systematic literature review, a hermeneutical analysis focusing the main issues of ethics in child and adolescent psychopharmacology is provided. Legal and regulatory aspects of psychopharmacological research in children are compared between the US and Europe. Relevant issues were informed assent and consent to research participation, minimal risk and burden of research, ethics of pharmacogenetics, research on "me-too" medications, and justice in global research. Additionally, the concern about undue influence of financial interests in research is also addressed. Conclusion: Incentives for the conduct of clinical trials with children comparable to those contained in US legislation are now provided in the EU. Research to develop "me-too" preparations may have no significant benefit for children, but can cause research burden and detract from clinically more important projects by utilizing limited investigator time and patient resources. Thus far, pharmacogenetic studies may bring more individualized treatment approaches into child psychiatry but they remain at present a promise for the future. Finally, the issues of avoiding undue influence from funders and conflicts of interest remain a prominent concern which can be solved by declaring conflicts and publishing all results of studies extensively.

AB - Objective: Research on psychopharmacological treatment in children and adolescents is the subject of ongoing ethical discussion, as minors with mental disorders constitute a vulnerable patient group. Considering the important legislative changes in pediatric research over the past decade in both the US and Western Europe, there is a need to review recent developments in this area. Method: Based on a systematic literature review, a hermeneutical analysis focusing the main issues of ethics in child and adolescent psychopharmacology is provided. Legal and regulatory aspects of psychopharmacological research in children are compared between the US and Europe. Relevant issues were informed assent and consent to research participation, minimal risk and burden of research, ethics of pharmacogenetics, research on "me-too" medications, and justice in global research. Additionally, the concern about undue influence of financial interests in research is also addressed. Conclusion: Incentives for the conduct of clinical trials with children comparable to those contained in US legislation are now provided in the EU. Research to develop "me-too" preparations may have no significant benefit for children, but can cause research burden and detract from clinically more important projects by utilizing limited investigator time and patient resources. Thus far, pharmacogenetic studies may bring more individualized treatment approaches into child psychiatry but they remain at present a promise for the future. Finally, the issues of avoiding undue influence from funders and conflicts of interest remain a prominent concern which can be solved by declaring conflicts and publishing all results of studies extensively.

KW - Children and adolescents

KW - Ethics

KW - Psychopharmacology

KW - Research

UR - http://www.scopus.com/inward/record.url?scp=77955636083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955636083&partnerID=8YFLogxK

U2 - 10.2174/138161210791959881

DO - 10.2174/138161210791959881

M3 - Article

VL - 16

SP - 2398

EP - 2406

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 22

ER -